| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
18210857532 18210857532 |
| Email: |
jk.info@jkchemical.com |
| Products Intro: |
Product Name:Prostaglandin D2
CAS:41598-07-6
Package:1Mg,2.5Mg
|
PROSTAGLANDIN D2 manufacturers
- Prostaglandin D2
-
- $223.00 / 100μg
-
2024-11-19
- CAS:41598-07-6
- Min. Order:
- Purity: 100%
- Supply Ability: 10g
|
| | PROSTAGLANDIN D2 Basic information |
| Product Name: | PROSTAGLANDIN D2 | | Synonyms: | 9,15-dihydroxy-11-oxo-,(5z,9-alpha,13e,15s)-prosta-13-dien-1-oicacid;prostaglandin D2 cell culture tested;prostaglandind2synthetichygroscopic;(5z,9α,13e,15s)-9,15-dihydroxy-11-oxoprosta-5,13-dien-1-oic-acid;7-[(1R,2R,5S)-5-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid;PGD2, (5Z,9α,13E,15S)-9,15-Dihydroxy-11-oxoprosta-5,13-dien-1-oic-acid;(5Z,13E,15S)-9α,15-Dihydroxy-11-oxoprosta-5,13-dien-1-oic acid;Prostaglandin D2,(5Z,9α,13E,15S)-9,15-Dihydroxy-11-oxoprosta-5,13-dien-1-oic-acid, PGD2 | | CAS: | 41598-07-6 | | MF: | C20H32O5 | | MW: | 352.47 | | EINECS: | 636-995-9 | | Product Categories: | | | Mol File: | 41598-07-6.mol |  |
| | PROSTAGLANDIN D2 Chemical Properties |
| Melting point | 68°C | | Boiling point | 406.07°C (rough estimate) | | alpha | +7.5°(D/21℃)(c=1,THF) | | density | 1.0601 (rough estimate) | | refractive index | 1.6120 (estimate) | | storage temp. | -20°C | | solubility | Chloroform (Slightly), Ethanol (Slightly), Methanol (Slightly), THF (Slightly) | | pka | 4.76±0.10(Predicted) | | form | White solid | | color | White to Light Orange | | biological source | synthetic | | BRN | 2170623 | | Stability: | Light Sensitive |
| Hazard Codes | T | | Risk Statements | 60-22 | | Safety Statements | 53-22-26-36 | | WGK Germany | 3 | | RTECS | UK7930000 | | F | 10 |
| | PROSTAGLANDIN D2 Usage And Synthesis |
| Description | Prostaglandin D2 (PGD2) is the major eicosanoid product of mast cells and is released in large quantities during allergic and asthmatic anaphylaxis. Mastocytosis patients produce excessive amounts of PGD2, which causes vasodilation, flushing, hypotension, and syncopal episodes. PGD2 is also produced in the brain via an alternative pathway involving a soluble, secreted PGD-synthase also known as β-trace. In the brain, PGD2 produces normal physiological sleep and lowering of body temperature. Further pharmacological actions include inhibition of platelet aggregation and relaxation of vascular smooth muscle. PGD2 inhibits human ovarian tumor cell proliferation with an IC50 of 6.8 μM. | | Uses | Prostaglandin D2 is a fatty acid compound present in the human body. Elevated levels of localized Prostaglandin D2 has been linked to hair loss and growth inhibition. It has also been seen to contribute to the activity of allergic asthma. | | Definition | ChEBI: A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- s
ereoisomer). | | Biochem/physiol Actions | Primary prostaglandin in brain; induces inflammation; stimulates adenylyl cyclase. | | in vivo | Prostaglandin D2 (PGD2; infused into the lateral ventricle; 5-50 pmol/min; for 6 hours between 20:00 and 2:00) induces sleep-wake profiles in A2AR KO mice[2]. | Animal Model: | Male WT and A2AR KO mice of the inbred C57BL/6 strain (weighing 23-27 g, 11-13 weeks old)[1] | | Dosage: | 5, 10, 20, or 50 pmol/min | | Administration: | Infused into the lateral ventricle; for 6 hours between 20:00 and 2:00 | | Result: | Induced sleep-wake profiles.
|
| | IC 50 | DP; Human Endogenous Metabolite |
| | PROSTAGLANDIN D2 Preparation Products And Raw materials |
| Raw materials | Prosta-5,13-dien-1-oic acid, 9-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-15-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-11-oxo-, (5Z,9α,13E,15S)- (9CI)-->Prosta-5,13-dien-1-oic acid, 9-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-15-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-11-hydroxy-, (5Z,9α,11α,13E,15S)- (9CI)-->Prosta-5,13-dien-1-oic acid, 9-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-15-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-11-hydroxy-, methyl ester, (5Z,9α,11α,13E,15S)- (9CI)-->Prosta-5,13-dien-1-oic acid, 9-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-15-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-11-[(tetrahydro-2H-pyran-2-yl)oxy]-, methyl ester, (5Z,9α,11α,13E,15S)- (9CI)-->Prosta-5,13-dien-1-oic acid, 15-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-9-hydroxy-11-[(tetrahydro-2H-pyran-2-yl)oxy]-, methyl ester, (5Z,9α,11α,13E,15S)- (9CI)-->5-Heptynoic acid, 7-oxo-, methyl ester-->2H-Pyran, tetrahydro-2-[[(1S)-1-[(1E)-2-iodoethenyl]hexyl]oxy]--->(4R)-(+)-T-BUTYLDIMETHYLSILOXY-2-CYCLOPENTEN-1-ONE |
|